Related Experiment Video

Updated: Nov 10, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.2K

Resistance to Molecularly Targeted Therapies in Melanoma

Meet Patel1, Adam Eckburg1, Shahina Gantiwala1

  • 1Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.

Cancers
|April 3, 2021
PubMed

Insights

Malignant melanoma, an aggressive skin cancer, often resists traditional treatments. Targeted therapies show promise but face acquired resistance, necessitating research into biomarkers like BRAF and MEK to improve patient outcomes.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Malignant melanoma is an aggressive skin cancer with poor prognosis in advanced stages.
  • Traditional treatments (surgery, radiation, chemotherapy) are often ineffective for metastatic melanoma.
  • Molecular targeted therapies offer improved efficacy and reduced toxicity compared to traditional methods.

Purpose of the Study:

  • To review key melanoma biomarkers (BRAF, MEK, RAS, c-KIT, VEGFR, c-MET, PI3K).
  • To discuss the mechanisms of acquired resistance to targeted melanoma therapies.
  • To highlight the need for novel therapeutic strategies to overcome resistance and improve patient prognosis.

Main Methods:

  • Literature review of recent studies on melanoma biomarkers and targeted therapies.
  • Analysis of mechanisms underlying acquired drug resistance in melanoma.
  • Description of specific biomarkers implicated in melanoma tumorigenesis and treatment resistance.

Main Results:

  • Several FDA-approved targeted therapies (e.g., tyrosine kinase inhibitors) are available for melanoma.
  • Acquired resistance to targeted therapies is a significant clinical challenge, driven by tumor mutations and alternative signaling pathways.
  • Understanding resistance mechanisms is crucial for developing next-generation melanoma treatments.

Conclusions:

  • Targeted therapies have revolutionized melanoma management but are limited by acquired resistance.
  • Further research into melanoma biomarkers and resistance pathways is essential for improving treatment efficacy.
  • Developing novel therapeutic approaches is critical to enhance survival rates for advanced melanoma patients.
Keywords:
TKIsbiomarkersmelanomamolecularly targeted therapiesresistance

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
818
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K